UK markets close in 7 hours 51 minutes

Hyloris Pharmaceuticals SA (0AB6.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
12.00-0.78 (-6.12%)
As of 05:15PM BST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 336.00M
Enterprise value 307.06M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)107.58
Price/book (mrq)6.27
Enterprise value/revenue 109.12
Enterprise value/EBITDA -20.44

Trading information

Stock price history

Beta (5Y monthly) 0.58
52-week change 33.43%
S&P500 52-week change 321.23%
52-week high 313.31
52-week low 30.00
50-day moving average 312.41
200-day moving average 312.42

Share statistics

Avg vol (3-month) 3258
Avg vol (10-day) 354
Shares outstanding 528M
Implied shares outstanding 6N/A
Float 8N/A
% held by insiders 156.62%
% held by institutions 10.48%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-548.55%

Management effectiveness

Return on assets (ttm)-18.54%
Return on equity (ttm)-33.95%

Income statement

Revenue (ttm)2.81M
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)80.20%
Gross profit (ttm)N/A
EBITDA -15.74M
Net income avi to common (ttm)-15.76M
Diluted EPS (ttm)-0.45
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)30.7M
Total cash per share (mrq)N/A
Total debt (mrq)1.75M
Total debt/equity (mrq)4.51%
Current ratio (mrq)5.09
Book value per share (mrq)1.97

Cash flow statement

Operating cash flow (ttm)-12.73M
Levered free cash flow (ttm)-7.78M